Brief: Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis
04/06/2025 12:16
Corvus Pharmaceuticals Inc CRVS.O: CORVUS PHARMACEUTICALS ANNOUNCES FULL DATA FROM COHORT 3 OF PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR ATOPIC DERMATITIS CORVUS PHARMACEUTICALS INC - COHORT 3 SHOWS CLINICALLY MEANINGFUL REDUCTION IN ITCH BY DAY 8 CORVUS PHARMACEUTICALS INC - ALL COHORTS SHOW STATISTICALLY SIGNIFICANT DIFFERENCE FROM PLACEBO AT DAY 28 CORVUS PHARMACEUTICALS INC - COHORT 3 SHOWS EARLIER AND DEEPER RESPONSES COMPARED TO COHORTS 1-2 Source text: ID:nGNX1kBxZS Further company coverage: CRVS.O
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental